Ambrx Biopharma (AMAM) has released an update.
Ambrx Biopharma, Inc. is on the cusp of becoming a wholly owned subsidiary of Johnson & Johnson, pending a merger that has already cleared a significant regulatory hurdle with the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Stockholders of Ambrx are scheduled to cast their votes on the merger agreement on March 6, 2024, with the transaction’s completion contingent on a majority approval. As the companies move closer to finalization, investors are encouraged to review the detailed information provided in the definitive proxy statement available on the SEC’s website and the respective companies’ websites.
For further insights into AMAM stock, check out TipRanks’ Stock Analysis page.
